Iron Sucrose 100 mg Injection

  • Medicine name- Nexiron
  • API- Iron Sucrose
  • Pack Size- Ampoule of 5 ml 
  • Strength- 100mg/5ml
  • Marketed by: Zydus Cadila
Get an Enquiry


Iron Sucrose is an iron replacement product indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease (CKD). 

Dosage and Side Effects

  • Iron Sucrose must only be administered intravenously either by slow injection or by infusion.  The dosage of Iron Sucrose is expressed in mg of elemental iron.  Each mL contains 20 mg of elemental iron.  

  • Administer Iron Sucrose 100 mg undiluted as a slow intravenous injection over 2 to 5 minutes, or as an infusion of 100 mg diluted in a maximum of 100 mL of 0.9% NaCl over a period of at least 15 minutes, per consecutive hemodialysis session. 

  • Administer Iron Sucrose 200 mg undiluted as a slow intravenous injection over 2 to 5 minutes or as an infusion of 200 mg in a maximum of 100 mL of 0.9% NaCl over a period of 15 minutes.  Administer on 5 different occasions over a 14 day period. 

  • Administer Iron Sucrose in 3 divided doses, given by slow intravenous infusion, within a 28 day period: 2 infusions each of 300 mg over 1.5 hours 14 days apart followed by one 400 mg infusion over 2.5 hours 14 days later.

Adult patients: The most common side effects are diarrhea, nausea, vomiting, headache, dizziness, hypotension, pruritus, pain in extremity, arthralgia, back pain, muscle cramp, injection site reactions, chest pain, and peripheral edema. 

Pediatric patients: The most common side are headache, respiratory tract viral infection, peritonitis, vomiting, pyrexia, dizziness, cough, nausea, arteriovenous fistula thrombosis, hypotension, and hypertension.

Warning and Precautions

  • Hypersensitivity Reactions: Observe signs and symptoms of hypersensitivity during and after administration for at least 30 minutes and until clinically stable following completion of each administration. Only administer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions.

  • Hypotension: May cause hypotension. Monitor for signs and symptoms of hypotension during and following each administration.  

  • Iron Overload: Regularly monitor hematologic responses during therapy.  Do not administer to patients with iron overload.